» SynAct Pharma ready for phase IIb and list change
» Top 5 life science stocks 2022 – first half of the year
» Ultimovac's study in malignant melanoma is fully recruited
» Immunicum changes name to Mendus
» Hectic half-year ahead for Pharmacologist
Read BioStock's newsletter for v.25 here.
Morning news
Medfield Diagnostics The rights issue is oversubscribed. Read more.
BioGaia launches product to promote respiratory health in children. Read more.
Micropos SEK 938 is added through share subscription via redemption of options. Read more.
PExA announces that a new scientific publication shows that recognized important biomarkers can be measured in PEx samples. Read more.
Marking announces that their SARS-CoV-2 vaccine study has been approved in Bangladesh. Read moreThe company has also updated the composition of the board. Read more.
Pharmiva will discuss the importance of new innovations in women's health in Almedalen. Read more.
Aino Health is holding a panel discussion in Almedalen about securing millions of jobs in the EU. Read more.
Raphael Gruber becomes medical director at 2cureX. Read more.
See the presentations from BioStock Life Science Spring Summit
Communiqués:
BrainCool Orthoma Hansa Biopharma OncoZenge
Notifications of share transactions and changes in equity:
Faron Pharmaceuticals Hansa Biopharma Episurf Medical Zealand Pharma Xbrane Biopharma Bone support
News received since Thursday lunch
Spago Nanomedical announced the outcome of the rights issue. Read more.
Saniona announced positive topline results from the Phase I study with SAN711. Read more.
Pila Pharma initiated toxicological studies. Read more.
A share transaction carried out by a person related to Carlos de Sousa, CEO of Ultimovacs, was reported by the company. Read more.
Cessatech reported green light for experiments with CT001. Read more.
Bio-Works Technologies new product series GoBio will save time in the production phase. Read more.
Diamyd Medical joined the international consortium for type 1 diabetes. Read more.
Qlife Holding has presented at a conference in the USA. Read more.
cline updated about the project StemCART. Read more.
A study from AstraZeneca showed that chronic kidney disease is present in one in ten adults. Read more.
Promimic and Danco Medical has entered into a share transfer and shareholder agreement regarding Nano Processing. Read more.
Bioservo has recruited all 63 participants for the ongoing clinical study with Carbonhand. Read more.
Coloplast was awarded the AscenDrive contract for ostomy products with Prime minister. Read mer.
Ray Intelligence ends mentoring agreement with Eminova. Read more.
Genmab has submitted an application to the US FDA - for Epcoritamab. Read more.
Calmark has received additional orders from Italy. Read more.
The Swedish Competition Authority has approved the merger of Orioles and Euroapothecas Swedish pharmacy operations. Read more.
Diagonal Bio presented test results based on clinical samples from patients infected with respiratory viruses. Read more.
RaySearch Laboratories announced that Västerbotten Region has placed an order for RayStation-system to Norrland University Hospital. Read more.
Board and management of PExA utilizes existing warrants and that the newly appointed CEO purchases warrants. Read more.
Mentice completed the acquisition of ANCHORAGE. Read more.
Vivesto has appointed Robert Maiorana to acting CFO. Read more.
Biovicas The CFO will retire in December 2022. Read more.
IBT has appointed Maria Ekdahl to the CFO. Read more.
Lena Hagman, Executive Vice President Quality compliance, Regulatory & Medical Affairs is leaving Getinge. Read more.
This morning's price development
Winner: Alteco 32,3%, Egetis Therapeutics 17,5% Selectimmune Pharma 11,1%, Aptahem 9,3%, QuiaPEG Pharmaceuticals 8,4%
Förlorare: Double Bond Pharmaceutical B -6,5%, Infant Bacterial Therapeutics -6%. RhoVac -5,9%, AlzeCure Pharma -5,8%. Alive -5,7%
Index: OMXS30 1879 +0,35% Healthcare +0,25%
More articles from BioStock
» Arcede Pharma's CEO is ready for the Spotlight
» 10 benefits of Staybles treatment
» BioMarin's gene therapy treatment receives EU approval
» Lipum's work with its Target Product Profile
» Oncopeptides rush on EU notice